Charles Schwab Investment Management Inc. Boosts Holdings in CorVel Co. (NASDAQ:CRVL)

Charles Schwab Investment Management Inc. increased its stake in CorVel Co. (NASDAQ:CRVL - Free Report) by 203.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 261,644 shares of the business services provider's stock after buying an additional 175,408 shares during the period. Charles Schwab Investment Management Inc. owned 0.51% of CorVel worth $29,111,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Crossmark Global Holdings Inc. purchased a new stake in shares of CorVel in the 3rd quarter worth $298,000. Quest Partners LLC grew its holdings in CorVel by 95.1% during the 3rd quarter. Quest Partners LLC now owns 3,596 shares of the business services provider's stock worth $1,175,000 after acquiring an additional 1,753 shares in the last quarter. Premier Fund Managers Ltd bought a new stake in shares of CorVel in the 3rd quarter valued at about $918,000. Advisors Asset Management Inc. lifted its position in shares of CorVel by 121.7% in the 3rd quarter. Advisors Asset Management Inc. now owns 204 shares of the business services provider's stock worth $67,000 after purchasing an additional 112 shares during the period. Finally, Intech Investment Management LLC bought a new position in shares of CorVel during the third quarter valued at approximately $2,797,000. Hedge funds and other institutional investors own 51.36% of the company's stock.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of CorVel from a "buy" rating to a "hold" rating in a research note on Thursday, March 13th.

Remove Ads

Insider Transactions at CorVel

In related news, Director Steven J. Hamerslag sold 10,000 shares of the company's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $123.48, for a total transaction of $1,234,800.00. Following the transaction, the director now directly owns 314,000 shares of the company's stock, valued at $38,772,720. This represents a 3.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey J. Michael sold 10,477 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $116.45, for a total value of $1,220,046.65. Following the completion of the sale, the director now directly owns 568,310 shares of the company's stock, valued at approximately $66,179,699.50. This represents a 1.81 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,200 shares of company stock valued at $3,824,115. Corporate insiders own 47.57% of the company's stock.

CorVel Stock Up 0.5 %

Shares of NASDAQ CRVL traded up $0.52 during mid-day trading on Friday, reaching $107.84. 98,710 shares of the company were exchanged, compared to its average volume of 106,477. CorVel Co. has a 1 year low of $76.20 and a 1 year high of $128.61. The firm has a 50-day moving average of $112.02 and a 200 day moving average of $114.11. The stock has a market cap of $5.54 billion, a price-to-earnings ratio of 63.44 and a beta of 1.06.

CorVel (NASDAQ:CRVL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The business services provider reported $0.46 earnings per share (EPS) for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.

CorVel Company Profile

CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.